Sequenom Launches Public Offering of Common Stock

Sequenom Launches Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) today announced that it has filed a preliminary prospectus supplement to an automatically effective shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 5,500,000 shares of its common stock. In connection with this offering, Sequenom plans to grant to the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock. All of the shares are being offered by Sequenom. Sequenom expects the net proceeds from the offering to be used for the development of diagnostic tests for use on its MassARRAY(R) system and other platforms, and for general corporate purposes.

Lehman Brothers Inc. and UBS Investment Bank are acting as joint book-running managers in this offering. The co-managers for the offering are Leerink Swann & Co., Inc., Lazard Capital Markets LLC, Oppenheimer & Co., Inc. and Rodman & Renshaw, LLC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities may be made only by means of the prospectus supplement, related prospectus and any supplemental information relating to the offering. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Lehman Brothers Inc. by e-mail at [email protected], by phone at 888.603.5847, by fax at 631.254.7140, or by mail at Lehman Brothers Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, or from UBS Securities LLC, 299 Park Avenue, New York, NY 10171 Attn: Prospectus Department, or by telephone toll free at 888-827-7275, extension 3884.

Forward-Looking Statements

This press release contains forward-looking statements, including statements relating to Sequenom's expectations regarding the completion and size of the proposed public offering and its expected use of proceeds from the offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and Sequenom cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Sequenom will be able to complete the public offering on the anticipated terms, or at all. Additional risks and uncertainties relating to Sequenom and its business are detailed from time to time in Sequenom's reports filed with the Securities and Exchange Commission and in the prospectus supplement related to the proposed offering. Sequenom undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Sequenom's expectations.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.